Summer 2022
August 30, 2022
Article
The investigators retrospectively analysed treatment-naive eyes with DMO which received intravitreal treatment with either ranibizumab 0.5 mg or aflibercept 2 mg. All data were collected via Fight Retinal Blindness! registry.
August 18, 2022
Article
Foundation Fighting Blindness is a driving force in advancing retinal gene therapies into clinical trials.
August 15, 2022
Article
CAM encourages corneal healing in patients with ocular surface disease.
August 11, 2022
Article
Dr Jayanth Sridhar shares a day in the life of an academic retina specialist.
August 10, 2022
Article
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.